<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322526</url>
  </required_header>
  <id_info>
    <org_study_id>PRO16050133</org_study_id>
    <nct_id>NCT04322526</nct_id>
  </id_info>
  <brief_title>Study of Naltrexone-Induced Blockade of Antidepressant Effects</brief_title>
  <acronym>SONRISA2</acronym>
  <official_title>Naltrexone-induced Blockade of Neural Responses Induced by Fast-Acting Antidepressant Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marta Peciña, MD PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brain &amp; Behavior Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine whether antidepressant placebo effects and contextual
      cues broadly, can be blocked by one single dose of the µ-opioid antagonist naltrexone. To
      test this hypothesis, un-medicated, patients with MDD completed a randomized, double-blind,
      placebo-controlled, cross-over study of 50mg of the µ-opioid antagonist naltrexone or
      matching placebo, immediately before a Pharmaco-fMRI scanning session.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuroimaging offers a precise and objective way to characterize the neural and molecular
      basis of the antidepressant response in humans. Furthermore, the combination of neuroimaging
      with pharmacological manipulations opens the possibility of investigating drug-induced brain
      changes associated with behavioral responses.

      In this study, the investigators aimed to whether antidepressant placebo effects and
      contextual cues broadly can be blocked by one single dose of the µ-opioid antagonist
      naltrexone. To assess trial by trial manipulation of antidepressant placebo effects inside of
      the scanner, the investigators have developed and piloted an fMRI task, specifically designed
      to record and modulate mood improvement using simulated neurofeedback. In a pilot study using
      this task, patients with MDD who reported acute mood improvement in response to positive
      neurofeedback, showed increased blood-oxygen-level-dependent (BOLD) responses in the ACC, and
      in particular, the rostral ACC (rACC), a reliable marker of treatment response in depression,
      and analgesic effects. In summary, these preliminary studies demonstrate 1) the contribution
      of the opioid system to the formation of antidepressant effects in MDD; and 2) increased rACC
      BOLD responses in patients who reported acute mood improvement induced by positive
      neurofeedback after a fast-acting antidepressant.

      Still, the opioid modulation of acute mood improvement and rACC BOLD responses in patients
      with MDD has not been investigated, which justifies the research proposed in this
      application. Based on this preliminary evidence, The investigators hypothesize that
      antidepressant effects in patients with Major Depression rely on opioid modulation of rACC
      activity, and therefore can be partially or totally blocked using the selective µ-opioid
      antagonist naltrexone.To test this hypothesis, 20 un-medicated, patients with MDD completed a
      randomized, double-blind, placebo-controlled, cross-over study of 50mg of the µ-opioid
      antagonist naltrexone or matching placebo, immediately before a Pharmaco-fMRI scanning
      session. The study aims to:

      AIM 1: Evaluate the effect of naltrexone on acute mood improvement and rostral anterior
      cingulate (rACC) BOLD activity induced by positive neurofeedback after a fast-acting
      antidepressant. The investigators hypothesize that naltrexone-induced blockade of µ-opioid
      receptors will reverse the acute mood improvement and increased rACC BOLD activity induced by
      positive neurofeedback.

      AIM 2: Determine the extent to which individual differences in the rACC BOLD activity induced
      by positive neurofeedback after a fast-acting antidepressant predict acute mood improvement.
      The investigators hypothesize that increased rACC BOLD activity induced by positive
      neurofeedback will be associated with greater acute mood improvement.

      AIM 3: Define the role of the rACC BOLD activity induced by positive neurofeedback as a
      mediator of the effect of group (naltrexone versus placebo) in acute mood improvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">July 15, 2018</completion_date>
  <primary_completion_date type="Actual">July 15, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a pharmaco-fMRI study of one single dose of naltrexone or placebo followed by an fMRI session in a crossover design.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD Responses in the rACC Cortex During the Processing of Contextual Cues at Baseline (Post-placebo)</measure>
    <time_frame>[Approximately at day 1, 7]</time_frame>
    <description>In order to identify the neural correlates of contextual processing, we examined changes in blood oxygenation level-dependent (BOLD) signal during the post-placebo fMRI scanning session.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Naltrexone-induced Changes in BOLD Responses in the rACC Cortex During the Processing of Contextual Cues (Placebo vs. Naltrexone)</measure>
    <time_frame>[Approximately at day 1, 7]</time_frame>
    <description>In order to identify naltrexone-induced changes in the neural correlates of contextual processing, we examined changes in blood oxygenation level-dependent (BOLD) during the fMRI scanning session between Naltrexone vs. placebo pill.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Naltrexone, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate neural responses during the Contextual Framing and the Antidepressant fMRI Task.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then naltrexone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 50 Mg Oral Tablet</intervention_name>
    <description>Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours).</description>
    <arm_group_label>Naltrexone, then placebo</arm_group_label>
    <arm_group_label>Placebo, then naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.</description>
    <arm_group_label>Naltrexone, then placebo</arm_group_label>
    <arm_group_label>Placebo, then naltrexone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, age 18-55 years; fluent in English and with the capacity to understand the
             nature of the study and sign the written informed consent since the research
             instruments used in this study are not available in other languages;

          -  Written informed consent obtained;

          -  Outpatients with a current primary diagnosis of nonpsychotic Major Depressive Disorder
             (MDD) per the Mini-International Neuropsychiatric Interview (M.I.N.I) with or without
             certain anxiety disorders (e.g., generalized anxiety, panic, agoraphobia, social
             phobia, and specific phobia); HDRS-17 score of ≥ 16 at Screening Visit;

          -  No more than one failed antidepressant trial of adequate dose and duration, as defined
             by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire
             (MGH-ATRQ);

          -  Participants will need to be antidepressant medication-free for at least 21 days prior
             to the collection of imaging data (five weeks for fluoxetine). However, individuals
             currently taking antidepressants will not be eligible to enroll in the study, even if
             they are willing to stop their medications.

        Exclusion Criteria:

          -  Currently taking opioid analgesics or in acute opioid withdraw.

          -  Pregnant or breastfeeding or plan to become pregnant over the duration of the study;

          -  History (lifetime) of psychotic depressive, schizophrenic, bipolar (I, II, or NOS),
             schizoaffective, or other Axis I psychotic disorders;

          -  Meeting M.I.N.I. criteria for substance dependence in the last 6 months, except for
             nicotine, or substance abuse in the last 2 months;

          -  Requiring immediate hospitalization for psychiatric disorder or have an unstable
             general medical condition (GMC) that will likely require hospitalization or to be
             deemed terminal (life expectancy &lt; 6 months after study entry);

          -  Requiring medications for their GMCs that contraindicate treatment with naltrexone;

          -  Having epilepsy or other conditions requiring an anticonvulsant;

          -  Receiving or have received during the current episode vagus nerve stimulation, ECT, or
             rTMS.

          -  Currently taking any psychiatric medication or other potential augmenting agents
             (e.g., T3 in the absence of thyroid disease, lithium, buspirone); Taking thyroid
             medication for hypothyroidism may be included only if they have been stable on the
             thyroid medication for 3 months;

          -  Receiving therapy that is depression specific, such as CBT or Interpersonal
             Psychotherapy of Depression (participants can participate if they are receiving
             psychotherapy that is not targeting the symptoms of depression, such as supportive
             therapy, marital therapy);

          -  Currently actively suicidal or considered a high suicide risk;

          -  Currently enrolled in another study, and participation in that study contraindicates
             participation in this study;

          -  Any reason not listed herein yet, determined by the site PI and research staff that
             makes participation in the study hazardous.

          -  Having any contraindication for the performance of an MRI, such as: the presence of
             metal implants or foreign metallic objects (e.g., braces or extensive dental work),
             severe claustrophobia, or inability to tolerate the scanning procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Peciña, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellefield Towers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <results_first_submitted>March 30, 2020</results_first_submitted>
  <results_first_submitted_qc>March 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2020</results_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Marta Peciña, MD PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NIfTI-formatted images for imaging, documentation, and code (https://github.com/) developed as part of this project will be shared upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Immediately following publication upon request. No end date.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT04322526/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone, Then Placebo</title>
          <description>In the naltrexone and then placebo arm, participants receive one-dose naltrexone 50mg one hour before a first fMRI scanning session on visit 1 followed by a one-dose placebo pill one hour before a second fMRI scanning session on visit 2.
Naltrexone 50 Mg Oral Tablet: Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours).
Placebo oral tablet: Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Naltrexone</title>
          <description>In the placebo and then naltrexone arm, participants receive one-dose of placebo pill one hour before a first fMRI scanning session on visit 1 followed by a one-dose naltrexone 50mg one hour before a second fMRI scanning session on visit 2.
Naltrexone 50 Mg Oral Tablet: Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours).
Placebo oral tablet: Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (1day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone, Then Placebo</title>
          <description>In the naltrexone and then placebo arm, participants receive one-dose naltrexone 50mg one hour before a first fMRI scanning session on visit 1 followed by a one-dose placebo pill one hour before a second fMRI scanning session on visit 2.
Naltrexone 50 Mg Oral Tablet: Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours).
Placebo oral tablet: Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Then Naltrexone</title>
          <description>In the placebo and then naltrexone arm, participants receive one-dose of placebo pill one hour before a first fMRI scanning session on visit 1 followed by a one-dose naltrexone 50mg one hour before a second fMRI scanning session on visit 2.
Naltrexone 50 Mg Oral Tablet: Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours).
Placebo oral tablet: Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="5.2"/>
                    <measurement group_id="B2" value="25.9" spread="8.2"/>
                    <measurement group_id="B3" value="25.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BOLD Responses in the rACC Cortex During the Processing of Contextual Cues at Baseline (Post-placebo)</title>
        <description>In order to identify the neural correlates of contextual processing, we examined changes in blood oxygenation level-dependent (BOLD) signal during the post-placebo fMRI scanning session.</description>
        <time_frame>[Approximately at day 1, 7]</time_frame>
        <population>The goal of aim one was to identify the neural correlates of antidepressant placebo effects. This aim was accomplished by examining the neural responses to the Antidepressant placebo fMRI task during the placebo session only, regardless of whether participants were assigned to the placebo-naltrexone or the naltrexone-placebo intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>fMRI BOLD Responses in the rACC Cortex (Placebo Session)</title>
            <description>We examined baseline brain measures of contextual processing during the placebo session only. In particular, we obtained whole-brain BOLD fMRI responses during the processing of contextual cues and extracted BOLD signal measures in the rACC.
Post-naltrexone brain responses were not used for this analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>BOLD Responses in the rACC Cortex During the Processing of Contextual Cues at Baseline (Post-placebo)</title>
          <description>In order to identify the neural correlates of contextual processing, we examined changes in blood oxygenation level-dependent (BOLD) signal during the post-placebo fMRI scanning session.</description>
          <population>The goal of aim one was to identify the neural correlates of antidepressant placebo effects. This aim was accomplished by examining the neural responses to the Antidepressant placebo fMRI task during the placebo session only, regardless of whether participants were assigned to the placebo-naltrexone or the naltrexone-placebo intervention.</population>
          <units>BOLD signal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in BOLD signal in the rACC during the processing of contextual cues (pleasant &gt; unpleasant).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Naltrexone-induced Changes in BOLD Responses in the rACC Cortex During the Processing of Contextual Cues (Placebo vs. Naltrexone)</title>
        <description>In order to identify naltrexone-induced changes in the neural correlates of contextual processing, we examined changes in blood oxygenation level-dependent (BOLD) during the fMRI scanning session between Naltrexone vs. placebo pill.</description>
        <time_frame>[Approximately at day 1, 7]</time_frame>
        <population>The goal of aim two was to investigate the effects of one single dose of naltrexone on the neural correlates of antidepressant placebo effects. This aim was accomplished by examining changes in the neural responses to the Antidepressant placebo fMRI task from the naltrexone to the placebo session, regardless of the order of each intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>fMRI BOLD Responses in the rACC Cortex (Naltrexone vs Placebo)</title>
            <description>We examined naltrexone-induced changes in brain signal during the processing of contextual cues by extracting brain responses in the rACC and comparing then during the baseline (placebo only) and the naltrexone session using paired-t test statistical analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Naltrexone-induced Changes in BOLD Responses in the rACC Cortex During the Processing of Contextual Cues (Placebo vs. Naltrexone)</title>
          <description>In order to identify naltrexone-induced changes in the neural correlates of contextual processing, we examined changes in blood oxygenation level-dependent (BOLD) during the fMRI scanning session between Naltrexone vs. placebo pill.</description>
          <population>The goal of aim two was to investigate the effects of one single dose of naltrexone on the neural correlates of antidepressant placebo effects. This aim was accomplished by examining changes in the neural responses to the Antidepressant placebo fMRI task from the naltrexone to the placebo session, regardless of the order of each intervention.</population>
          <units>changes in BOLD signal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in BOLD fMRI signal from the Placebo vs. the Naltrexone session.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mechanistic hypothesis: naltrexone will block contextual processing.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>[Approximately at day 1, 7]</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo oral tablet: Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone</title>
          <description>Naltrexone 50 Mg Oral Tablet: Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, gastrointestinal discomfort, vomiting.</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness/drowsiness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Shaking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study does not have a healthy control condition, and therefore, results cannot be generalized beyond depression.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Marta Pecina</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>734-945-2473</phone>
      <email>pecinam@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

